MBX Biosciences announced a significant leadership transition, with CEO Kent P. Hawryluk stepping down effective July 13, 2026. The company has appointed its executive Chairman, Steven Hoerter, as the new President and CEO, and has made interim CFO John Smither's role permanent, effective the same day.
Key Details
- CEO Transition: Kent P. Hawryluk departed as CEO and board member. The filing states his departure is not due to any disagreement. He will provide advisory services through August 16, 2026.
- New CEO Appointment: Steven Hoerter was appointed President & CEO with a base salary of $665,000 and a target bonus of 60%. His equity awards include options for 331,000 shares and 71,000 restricted stock units (RSUs).
- New CFO Appointment: John Smither was promoted from interim to permanent CFO. His compensation includes a base salary of $530,000, a 40% target bonus, a $150,000 relocation bonus, and equity awards of options for 130,000 shares and 28,000 RSUs.